Nightstar Therapeutics News Releases https://ir.nightstartx.com/ Nightstar Therapeutics News Releases en Nightstar Therapeutics PLC Shareholders Approve Scheme of Arrangement for Acquisition By Biogen at General Meeting and Court Meeting Held on 8 May 2019 https://ir.nightstartx.com/news-releases/news-release-details/nightstar-therapeutics-plc-shareholders-approve-scheme NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON , May 08, 2019 (GLOBE NEWSWIRE) -- Wed, 08 May 2019 09:36:00 -0400 Nightstar Therapeutics News Releases 7511 Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Nightstar Shareholders Vote “FOR” Proposed Acquisition by Biogen https://ir.nightstartx.com/news-releases/news-release-details/leading-proxy-advisory-firms-iss-and-glass-lewis-recommend WALTHAM, Mass. and LONDON , April 26, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar") (NASDAQ: NITE) today announced that both leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. Fri, 26 Apr 2019 02:00:00 -0400 Nightstar Therapeutics News Releases 7471 Nightstar Therapeutics plc Announcement of Expiry of HSR Waiting Period and Satisfaction of Antitrust Condition https://ir.nightstartx.com/news-releases/news-release-details/nightstar-therapeutics-plc-announcement-expiry-hsr-waiting NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON , April 16, 2019 (GLOBE NEWSWIRE) -- Tue, 16 Apr 2019 08:35:00 -0400 Nightstar Therapeutics News Releases 7456 Recommended Acquisition of Nightstar Therapeutics plc by Tungsten Bidco Limited, a Wholly-Owned Subsidiary of Biogen Switzerland Holdings GmbH; Posting of Scheme Document https://ir.nightstartx.com/news-releases/news-release-details/recommended-acquisition-nightstar-therapeutics-plc-tungsten NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON , April 09, 2019 (GLOBE NEWSWIRE) -- On 4 Tue, 09 Apr 2019 08:55:00 -0400 Nightstar Therapeutics News Releases 7371 Nightstar Therapeutics plc reaches agreement to be acquired by Biogen https://ir.nightstartx.com/news-releases/news-release-details/nightstar-therapeutics-plc-reaches-agreement-be-acquired-biogen Biogen to acquire Nightstar for US$ 25.50 per share in cash Transaction expected to be completed by mid-year 2019 WALTHAM, Mass. and LONDON , March 04, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (" Nightstar ") (NASDAQ: NITE), a clinical-stage gene therapy company developing treatments for Mon, 04 Mar 2019 02:01:00 -0500 Nightstar Therapeutics News Releases 7221 Nightstar Announces Planned Initiation of Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and Reports Third Quarter 2018 Financial Results https://ir.nightstartx.com/news-releases/news-release-details/nightstar-announces-planned-initiation-phase-23-expansion-study Phase 2/3 Expansion Study to Include No-Sham Control Arm in Alignment with FDA Draft Guidance on Development of Gene Therapy Products for Retinal Disorders Preliminary Efficacy Data from Phase 2/3 Expansion Study Expected in Mid-2019 WALTHAM, Mass. and LONDON , Nov. Tue, 13 Nov 2018 01:00:00 -0500 Nightstar Therapeutics News Releases 6981 Nightstar Therapeutics to Participate in Multiple Conferences in November https://ir.nightstartx.com/news-releases/news-release-details/nightstar-therapeutics-participate-multiple-conferences-0 WALTHAM, Mass. and LONDON , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will participate in the following investor conferences in Thu, 08 Nov 2018 06:05:00 -0500 Nightstar Therapeutics News Releases 6966 Nightstar Therapeutics to Present at Chardan Genetic Medicines Conference https://ir.nightstartx.com/news-releases/news-release-details/nightstar-therapeutics-present-chardan-genetic-medicines WALTHAM, Mass. and LONDON , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company plans on presenting at the Chardan Genetic Medicines Conference , Thu, 04 Oct 2018 06:05:00 -0400 Nightstar Therapeutics News Releases 6856 Nightstar Announces Closing of Public Offering and Full Exercise of Underwriters’ Option https://ir.nightstartx.com/news-releases/news-release-details/nightstar-announces-closing-public-offering-and-full-exercise WALTHAM, Mass. and LONDON , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the closing of its underwritten public offering of 4,600,000 American Depositary Tue, 02 Oct 2018 16:05:00 -0400 Nightstar Therapeutics News Releases 6851 Nightstar Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa https://ir.nightstartx.com/news-releases/news-release-details/nightstar-therapeutics-present-2018-cell-gene-meeting-mesa WALTHAM, Mass. and LONDON , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company plans on presenting at the Cell & Gene Meeting on the Mesa Mon, 01 Oct 2018 06:05:00 -0400 Nightstar Therapeutics News Releases 6836